[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 1.14% 22.25 254,203 09:32:15
Bid Price Offer Price High Price Low Price Open Price
22.00 22.50 22.25 22.00 22.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -6.77 -1.21 176
Last Trade Time Trade Type Trade Size Trade Price Currency
15:40:24 O 350 22.262 GBX

Scancell (SCLP) Latest News

More Scancell News
Scancell Investors    Scancell Takeover Rumours

Scancell (SCLP) Discussions and Chat

Scancell Forums and Chat

Date Time Title Posts
26/9/202117:45Using immunology to fight cancer.45,108
22/9/202114:38Scancell - Pot of Gold or POS?120
13/9/202122:22Fringe views (or are they?) discussion thread9
29/5/202115:28Only worth 4p on fundamentals - Beware Ramper Restassured620
23/11/202008:53charts etc908

Add a New Thread

Scancell (SCLP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scancell trades in real-time

Scancell (SCLP) Top Chat Posts

DateSubject
26/9/2021
09:20
Scancell Daily Update: Scancell Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 22p.
Scancell Holdings Plc has a 4 week average price of 21.50p and a 12 week average price of 19.25p.
The 1 year high share price is 28.25p while the 1 year low share price is currently 10.25p.
There are currently 791,917,828 shares in issue and the average daily traded volume is 482,408 shares. The market capitalisation of Scancell Holdings Plc is £176,201,716.73.
26/9/2021
10:22
inanaco: we have heard it all before ........... opposition to going all in ...lOZAN indeed i gave a very balanced reasoning as why ORPH was not the best bet for capital growth ... Ivy even taking a bet on his belief ... However your Critical of my £8 ..... in the light of ORPH current financial statements how does this compare ... ? The ALTERNATIVE VIEW $1,000,000,000 Share Price 30p You can work out the Loss yourself .... Ivyspivey - 13 Mar 2021 - 16:52:53 - 37999 of 45080 Using immunology to fight cancer. - SCLP Well we can try. Firstly it is profitable and generates plenty of cash so does not need to raise. Current global leader in HC studies with U.K. Govt contract of £46m and likely another £50m announced in next few weeks. Currently doing work with 4 of top 5 big pharma. Has ambitions to be a $1bn Company within 12-18 months based on current outlook. Has 4 potential disposals of non core assets again could total $1bn plus again within 6 months. The CEO has about £20m of his own money tied up and wants to buy more. All of the above does nit depend on any trial results as they get paid whether trial is a success or not. I am not saying that SCLP will not increase its share price more than ORPH it could if say Covid Vax comes good and SCIB1/ Combo and Modi 1 gets successful results. But if I was investing £300k then personally I would not risk all of it in SCLP which may 20 bag but also there is risk when I could stick say £200k in ORPH which imo has very little risk of going down and is very likely to go up at least 5 fold within 12 months and say a £100k in SCLP. I am not criticising your choice but equally please don’t have a go at someone who chooses a different path
21/9/2021
13:37
inanaco: is this is what you are on about Ivy ? Posts: 161 Price: 25.00 No Opinion RE: Fair Value21 Sep 2021 11:46 Patience will be rewarded here Buy one And get four free 1-poolbeg 2- Disease in Motion 3- Immutex 4-prep biopharma 5- And also keep your open orphan shares if that lot is worth 15p a share and are included in the current share price what happens to the share price if you remove 15p/share worth of assets ??
17/9/2021
09:42
emptyend: Indeed, Gazza.This is always the problem when a cuckoo occupies the nest and attempts to push everything else out in order to make room for its massive bulk (deluded ego).To summarise:1)Scancell NAV = irrelevant historic accounting number that excludes IP value2)Scancell share price = market's best estimate of the (share of) value of the whole company, including IP, taking account of everything known at the time3)NAV of funds that hold Scancell = irrelevant to Scancell or its shareholders (but incorporate the mark-to-market share price)4) Conversion of the CLNs will occur at 13p per share as the loan term expiry approaches and will likely trigger a mandatory bid at 13p per share unless there is some prior or simultaneous corporate event that ensures Redmile remain below 30% even after CLN conversion.So....EVERYTHING connected to NAV is (virtually) irrelevant to Scancell and its shareholders. The only thing that matters is whether the market opinion (expressed through the share price) of the value of Scancell's whole company value (including IP) is accurate. It is my view that it isn't and that the current share price is between 30% and 50% less than "it should be" for the current position with major products entering trials..........but that is "OK" and largely to be expected, because the value of the IP is intrinsically uncertain until the very moment when a value is crystallised via some form of deal. For what it is worth, I am expecting the company to be worth around £2 billion by the end of 2023 - but the share price path to that destination will be marked by lots of flat-lining and 3-4 near-vertical ascents.I'm offline for the rest of the day, so don't expect any responses.
16/9/2021
10:08
inanaco: actually no .. because i kept buying but ... the value even if i didn't buy anymore did not change it actually went up .. thus my "money" never got diluted ... people measure the dilution by the value difference ... for instance share price 5.5p cashed raised at 3p ... = dilution but if the share price went up "how does that lower the value " which is what the word dilution means any calculation has to have a measurable reaction ..... other wise its NULL 0=0 how can you have "negative dilution" ? it does not make sense Bermudashorts - 27 Jul 2020 - 09:08:08 - 31074 of 44693 Using immunology to fight cancer. - SCLP Inanaco, The IP hasn't been diluted, it's as strong and complete as it was the day before funding was announced. I think the issue here is just the choice of the words used when describing what has been diluted. I think we all agree, (including yourself) that on the day the placing shares are admitted to AIM each of our shareholdings will have been diluted - we will own a smaller part of the Company - fact. Whether the value of our diluted shares goes up or down depends entirely on how the Company performs so you are correct in saying that dilution doesn't automatically equate to financial loss. Can't we just leave it at that? """""- we will own a smaller part of the Company - fact."""" NO it was ... If the new shares are issued for proceeds at least equal to the pre-existing price of a share, then there is no negative dilution in the amount recoverable. .The old owners just own a smaller piece of a bigger company However, voting rights at stockholder meetings are decreased. """"The old owners just own a smaller piece of a bigger company""" that is the fact dilution ........ the action of making something weaker in force, content, or value. effect IP got diluted by more shareholders of it ....
16/9/2021
08:49
inanaco: anyway these two posts are spot on .............. so unless you can show any maths that disagrees with ONW and mine ....... Good Luck to you mind you ONW will pontificate a difference when none exists ... the last thing he will ever post is ... i was right that's due as we Know to his biggest Gaff ... Moditope Trumps Immunobody "the Jelly Spanner "approx 2014" since then he has only delivered Hissy fits inanaco - 15 Sep 2021 - 08:45:32 - 44619 of 44680 Using immunology to fight cancer. - SCLP ip got diluted/ shares in issue exactly which is what ONW's and my post explained no difference the IP Value has always been divided by shares in issue ..... and if you add more shares of the same value which is what the cash raise did the only effect is the IP/share ratio thus the IP got diluted by more shares of it ........ the share price is a Cake (mcap) ..... and so was the IP the share price cake got bigger (mcap) ............. the Ip didn't inanaco - 15 Sep 2021 - 08:28:17 - 44617 of 44680 Using immunology to fight cancer. - SCLP by the way bermuda Bermudashorts14 Sep '21 - 19:11 - 44598 of 44616 0 0 0 Inanaco, Yes the preclinical science has expanded greatly but so has the number of shares in issue, so your £8 per share now equates to a market cap of over £6.5 billion which equals over $9 billion. yes the "ip got diluted" as per ONW and my posts on dilutio
09/9/2021
15:51
oldnotwise: Gazza and EE, I think the measure of Scancell's share price movement since February is rather one of relative stability than drift. In fact the stability is quite remarkable in my view. As we know from the past that Scancell with no news resulted in price reductions not stability.... Before anyone says anything the SA announcement and previous announcements since February have not resulted in significant and lasting share price increases. People might like to reflect on that .... IE why not. I believe we are now seeing the Company beginning to be recognised as one for buying and holding rather than buying, seeing the share price fall, selling and then chasing the share price on the next "engineered" good news. Looks to me like there's now the confidence to wait and expect the P1 trial results (a probable share price + situation).... a further period of relative Stability (assuming all goes well) until early data from P2 trials.... All of this against the backdrop of the CLNs maturing in about one year's time (which will mean Scancell will need to find GBP17M (from memory - easily checked) to repay the debt. My view/hope is that this will not happen as a takeover of all (or part of the Company) may well occur which will allow a partial exit by the IIs, Scancell becoming Debt free with a view to awaiting fuller P2 data (should the entire IP not be sold before the Debts falls due). All a bit pie in the sky maybe but I think we need to look at the structure of RM's holdings within the Company and then ask why was this structure asked for and agreed to. I say this because I very much doubt that the BOD made the offer of the mix of CLNs and direct equity. EDIT Apologies, i should have added that we shouldn't forget that our IIs will have stakes in other Bios that might be interested in bits (or all) of Scancell, and by virtue of the size of their holdings (our IIs that is) it may not be Scancell's choice as to how it goes forward after the CLNs fall due. Certainly one significant holder has alluded to this.... talk of Scancell going it alone may be easily nipped in the bud by looking at the weight of voting shares that could easily be bought to bear if needed. There are no givens in this game. AIMO ATB
09/9/2021
12:39
gazza: Hi tosh, Trust you are well. I was merely responding to a request from EE. I know any figures are "pure conjecture" as you say. I find it useful to define the bounds of reality however wide that is. Some people go beyond those realms into the impossible. It would be like buying a £2 lottery ticket and hoping to win a trillion pounds - the money just doesn't exist. You can also identify the possible but unlikely , for example, win 8 million pounds. The realms of possibility (but unlikely) in terms of SCLP share price is 4p - £64.00 Possible and not totally unlikely - 48p - £2.69 Personally, I find these extremes useful. If others don't just ignore them.
09/9/2021
11:35
oldnotwise: Inanaco I actually haven't read about the last ten posts from you (it may even be more by now). All I'll say is that you were projecting share prices for Scancell nine years ago based on your embarrassingly naive attempts to value Scancell then. You had no idea of how Pharma would assess a company such as Scancell. As a result of your "attempts to value Scancell" you produced a timetable of share price progression which if I remember correctly took the share price to around 230p within appx six months of 2012. Your track record is abysmal. You seem to have learned NOTHING about valuing Biotechs in the last (nearly) ten years, yet you lecture others who have a much greater understanding of the Commercial valuation of Bios. Anyone who gets invilved with your naive attempts are wasting their time. Better to simply ignore your comments. Unlike Scancell's IP they are valueless. AIMO
08/9/2021
13:28
inanaco: EE you are making the biggest mistake ... because Scancell will only Licence or partner parts of the IP the share price has nothing to do with it .. because that is reactive to the News given to the market rather than a prediction of news presented to the market so for instance if Scancell announce Roche was considering a deal on X product and a deal should be concluded soon ... what would the share price do ? it would try and value a deal and move accordingly so the current share price is based on No deal at present ... put possibly in two years .. on the cancer platforms Covid is still in the Grant window ... but only to phase 1
07/9/2021
10:08
inanaco: The alternative View ... share price was drifting on the floating boat ... still wind means those escaping France are trying again ...... the effect on the share price with Loz is zero ... so any view is pointless as he has No Shares however ... bit of wind and the share price drifts up ... seems we have sails who would have thought that with all the news that is coming .. Lindy even gives you a detailed analysis of the competition ... all those apparently that could over take us, according to ivermectin Expert Ivy hTTps://www.scancell.co.uk/Data/Sites/1/media/docspres/paston-et-al-2021.pdf seems many still want to join the ""all about the number you hold club"" Tick Tock The builder .....
Scancell share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SCLP
Scancell
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 17:10:15